No clear answer
Fish oil: repair myelin in relapsing MS
relapsing MS · Vitamin D and nutritional supplements
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 220
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Fish oil, phase 3 | Phase 3 | 220 | 2016 | Other endpoint result For the intention-to-treat analyses Neuroaspis plp10 significantly reduced the ARR by 80%, (RRR, 0.20; 95% CI: 0.09 to 0.45; p=0.0001) and the risk of sustained progression of disability by 73% (HR, 0.27; 95% CI: 0.09 to 0.83; p=0.022) versus placebo, at 2 years. Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Nov 2026Status changed from Results pending to No clear answer
- Nov 2026Status changed from Being tested to Results pending
- Oct 2026First listed as Being tested
Related hypotheses
- Vitamin D and nutritional supplements: protect nerve tissue in relapsing MS
- Melatonin: protect nerve tissue in relapsing MS
- Vitamin D and nutritional supplements: slow disability worsening in relapsing MS
- Cholecalciferol: slow disability worsening in relapsing MS
- Ergocalciferol: slow disability worsening in relapsing MS
- Melatonin: slow disability worsening in relapsing MS
- Retinol: slow disability worsening in relapsing MS
- Vitamin D and nutritional supplements: reduce relapses and new lesions in relapsing MS
- Cholecalciferol: reduce relapses and new lesions in relapsing MS
- Curcumin: reduce relapses and new lesions in relapsing MS
- Melatonin: reduce relapses and new lesions in relapsing MS
- Omega-3 fatty acids: reduce relapses and new lesions in relapsing MS
- Retinol: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources.